Mumakore achangopfuura, mhedzisiro yeimmune checkpoint inhibitors pakurapa kweHodgkin's lymphoma (HL) inoshamisa, asi chirwere ichi chinoda kukundwa zvakanyanya. Sachigaro weMayo Clinic's Lymphoma Group Ansell akati.
Vatsvagiri paUniversity yeCalifornia, San Francisco uye St. Jude Vana Chipatara Chekutsvagisa muTennessee vakagadzirisa zvakavanzika zvekurapa makumi emakore apfuura, uye ivo vakawana paine shanduko dzemajini dzinogona kukonzera fa ..
Iyo FDA yakapa kuburitsa kwayo mushonga quizartinib kurapa kwekubudirira. Quizartinib iri FLT3 inhibitor iri pasi pekuferefetwa kwekurapwa kwevakuru varwere vakadzokerazve / vanodzora FLT3-ITD acute myeloi ..
US Food and Drug Administration yakabvumidza Venetoclax (Venclexta) yakasanganiswa ne rituximab (VenR) yekurapa kwevarwere vane chirwere chisingaperi cheLymphocytic leukemia (CLL) zvichibva pane diki dhata rechirwere (MRD) chechikamu ..
Zvinoenderana neakawanda-center kiriniki kuyedza inotungamirwa nevaongorori vepaStanford University Chikoro cheMishonga, mhando nyowani yeimmunotherapy inoita seyakachengetedzeka kuvarwere vane gomarara reropa inonzi non-Hodgkin's lymphoma.The therapy com.
Zvinoenderana nezvakabuda muchikamu chechipiri chekudzidza, kusanganiswa kwechemotherapy-yekuchengetedza chemotherapy drug azacitidine uye immune checkpoint inhibitor nivolumab (nivolumab) yakaratidza kuti mwero wekupindura uye kudzokororazve ..
On November 28, FDA approved the first rituximab (Rituxan, rituximab) biosimilar, Truxima (rituximab-abbs, Celltrion Inc.) for non-Hodgkin's lymphoma (NHL). Rituximab is a monoclonal antibody against CD20. It is widely used..
US FDA yakabvumira gilteritinib (Xospata) yekurapa varwere vakuru vane FLT3 mutation-positive relapse kana refractory acute myeloid leukemia ( AML ). Kana yakashandiswa negil..
Migumisiro ye-multi-center phase III kliniki yekuedza yakaratidza kuti kana varwere vakwegura vane chronic lymphocytic leukemia (CLL) vakarapwa nemishonga itsva yakanangwa ibrutinib kana ichienzaniswa neyaimbova commo.
Venetoclax (Venclexta) uye rituximab (Rituxan) inoshandiswa pamwe chete nekudzokazve / refractory chronic lymphocytic leukemia (CLL), zvichikonzera huwandu hwepamusoro husingaonekwe hushoma hwechirwere chesara (MRD), icho se.